Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

124 recalls · Class I, newest first

Class I · High risk

BD ChloraPrep Hi-Lite Orange 26 mL Applicator

Defective Delivery System: An increase in complaints identified endcap being loose or falling off upon activation releasing glass shards containing the solution.

Terminated Packaging defect CareFusion 213, LLC NDC 54365-400-38 D-0373-2021
Class I · High risk

Thumbs up 7 Red 70K capsules

Marketed Without An Approved NDA/ANDA: Products found to contain undeclared tadalafil and/ or sildenafil and vardenafil making them unapproved drugs for which the safety and efficacy have not been established and therefore subject to recall.

Terminated Chemical / undeclared Ummzy, LLC D-0664-2021
Class I · High risk

Shogun-X capsules

Marketed Without An Approved NDA/ANDA: Products found to contain undeclared tadalafil and/ or sildenafil and vardenafil making them unapproved drugs for which the safety and efficacy have not been established and therefore subject to recall.

Terminated Chemical / undeclared Ummzy, LLC D-0663-2021
Class I · High risk

Krazy Night capsule

Marketed Without An Approved NDA/ANDA: Products found to contain undeclared tadalafil and/ or sildenafil and vardenafil making them unapproved drugs for which the safety and efficacy have not been established and therefore subject to recall.

Terminated Chemical / undeclared Ummzy, LLC D-0662-2021
Class I · High risk

69MODE Blue 69 capsule

Marketed Without An Approved NDA/ANDA: Product found to be tainted with undeclared tadalafil and sildenafil, two FDA approved drugs making it an unapproved drug for which the safety and efficacy have not been established and therefore subject to recall.

Ongoing Chemical / undeclared Nuri Trading LLC D-0688-2021
Class I · High risk

Thumbs Up 7 White 11K capsule

Marketed Without An Approved NDA/ANDA: Product found to be tainted with undeclared tadalafil sildenafil, and vardenafil, FDA approved drugs making them an unapproved drug for which the safety and efficacy have not been established and therefore subject to recall.

Ongoing Chemical / undeclared Nuri Trading LLC D-0687-2021
Class I · High risk

Thumbs Up 7 Black 25K capsule

Marketed Without An Approved NDA/ANDA: Product found to be tainted with undeclared tadalafil, an FDA approved drug making this an unapproved drug for which the safety and efficacy has not been established and therefore subject to recall.

Ongoing Chemical / undeclared Nuri Trading LLC D-0686-2021
Class I · High risk

Shogun-X 7000 capsule

Marketed Without An Approved NDA/ANDA: Product found to be tainted with undeclared tadalafil and sildenafil, two FDA approved drugs making them unapproved drugs for which the safety and efficacy have not been established and therefore subject to recall.

Ongoing Chemical / undeclared Nuri Trading LLC D-0685-2021
Class I · High risk

Xultophy 100/3.6

Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.

Terminated Temperature excursion Novo Nordisk Inc NDC 0169-2911-90 D-0623-2021
Class I · High risk

TRESIBA FlexTouch

Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.

Terminated Temperature excursion Novo Nordisk Inc NDC 0169-2550-90 D-0621-2021
Class I · High risk

TRESIBA (insulin degludec injection)

Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.

Terminated Temperature excursion Novo Nordisk Inc NDC 0169-2662-90 D-0620-2021
Class I · High risk

TRESIBA FlexTouch

Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.

Terminated Temperature excursion Novo Nordisk Inc NDC 0169-2660-90 D-0619-2021

Recalls by year